Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center

INTRODUCTION: After the first case of Covid-19 was identified in Wuhan City, China, the numbers increased rapidly all over the world putting a huge burden on the entire healthcare system. Managing these cases posed a great challenge to the treating clinicians in the absence of targeted therapy. At t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohanty, Bijaya, Sunder, Ashok, Satyanarayan, Bhagyalakshmi, Kumar, Manish, Shukla, Rajiv, Ahmed, Asif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797123/
https://www.ncbi.nlm.nih.gov/pubmed/35136795
http://dx.doi.org/10.4103/jfmpc.jfmpc_578_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797123/
https://www.ncbi.nlm.nih.gov/pubmed/35136795
http://dx.doi.org/10.4103/jfmpc.jfmpc_578_21

Ejemplares similares